Select Page

Beyond speed: The value of a computational approach to drug discovery

Jun 2, 2020 | Blog | 0 comments

Daniel Gigante

We recently held an event with BioIDEA: Biotech vs COVID-19. During the event, our CEO, Andrew Satz, was asked the value of computational drug discovery beyond just speed. Andrew explained that while speed is important, it can also be dangerous, and is certainly not the only reason we’ve chosen a computational approach to drug discovery.

In addition to speed, computational technologies can aid in de-risking by creating models or simulations of lab outcomes. This leads to computer failure instead of lab failure, or, de-risking of the drug discovery and development process. Because of this decreased risk, we should expect a significant reduction in cost. This is beneficial for companies, but more importantly, it increases availability and reduces financial hardship for those in need of healing. Watch the clip below.


Submit a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...